Literature DB >> 18308149

The role of locoregional therapy in inflammatory breast cancer.

Wendy A Woodward1, Thomas A Buchholz.   

Abstract

Inflammatory breast cancer (IBC) is the most aggressive form of invasive breast cancer. The disease is associated with extensive local disease at the time of initial diagnosis requiring multidisciplinary treatment including neoadjuvant systemic therapy, surgery and comprehensive locoregional therapy. The clinical and pathological response to induction chemotherapy represents an important prognostic factor. IBC is otherwise associated with a high incidence of locoregional recurrence suggesting a critical role also for local modalities, particularly radiotherapy. The use of different schedules of treatment and possible combination approaches are reviewed and discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18308149     DOI: 10.1053/j.seminoncol.2007.11.009

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  9 in total

1.  Interaction of low molecular weight hyaluronan with CD44 and toll-like receptors promotes the actin filament-associated protein 110-actin binding and MyD88-NFκB signaling leading to proinflammatory cytokine/chemokine production and breast tumor invasion.

Authors:  Lilly Y W Bourguignon; Gabriel Wong; Christine A Earle; Weiliang Xia
Journal:  Cytoskeleton (Hoboken)       Date:  2011-11-29

2.  Radiotherapy of Breast Cancer-Professional Guideline 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.

Authors:  Csaba Polgár; Zsuzsanna Kahán; Olivera Ivanov; Martin Chorváth; Andrea Ligačová; András Csejtei; Gabriella Gábor; László Landherr; László Mangel; Árpád Mayer; János Fodor
Journal:  Pathol Oncol Res       Date:  2022-06-23       Impact factor: 2.874

3.  Current Surgical Management of Inflammatory Breast Cancer.

Authors:  Taiwo Adesoye; Anthony Lucci
Journal:  Ann Surg Oncol       Date:  2021-08-03       Impact factor: 5.344

4.  Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database.

Authors:  Natasha M Rueth; Heather Y Lin; Isabelle Bedrosian; Simona F Shaitelman; Naoto T Ueno; Yu Shen; Gildy Babiera
Journal:  J Clin Oncol       Date:  2014-06-02       Impact factor: 44.544

Review 5.  New Treatment Strategies for the Inflammatory Breast Cancer.

Authors:  Elena Vagia; Massimo Cristofanilli
Journal:  Curr Treat Options Oncol       Date:  2021-04-24

6.  A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer.

Authors:  Wendy A Woodward; Penny Fang; Lisa Arriaga; Hui Gao; Evan N Cohen; James M Reuben; Vicente Valero; Huong Le-Petross; Lavinia P Middleton; Gildy V Babiera; Eric A Strom; Welela Tereffe; Karen Hoffman; Benjamin D Smith; Thomas A Buchholz; George H Perkins
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-05-03       Impact factor: 8.013

7.  EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer.

Authors:  Bisrat G Debeb; Yun Gong; Rachel L Atkinson; Nour Sneige; Lei Huo; Ana Maria Gonzalez-Angulo; Mien-Chie Hung; Vicente Valero; Naoto T Ueno; Wendy A Woodward
Journal:  J Exp Clin Cancer Res       Date:  2014-07-23

8.  Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers.

Authors:  Audrey Monneur; Anthony Goncalves; Marine Gilabert; Pascal Finetti; Carole Tarpin; Christophe Zemmour; Jean-Marc Extra; Agnès Tallet; Eric Lambaudie; Jocelyne Jacquemier; Gilles Houvenaeghel; Jean-Marie Boher; Patrice Viens; François Bertucci
Journal:  Oncotarget       Date:  2017-07-31

9.  The Impact of Locoregional Therapy in Nonmetastatic Inflammatory Breast Cancer: A Population-Based Study.

Authors:  Mahvish Muzaffar; Helen M Johnson; Nasreen A Vohra; Darla Liles; Jan H Wong
Journal:  Int J Breast Cancer       Date:  2018-06-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.